INOVIO PHARMACEUTICALS INC (INO)
US45773H4092 - Common Stock
Overall INO gets a fundamental rating of 3 out of 10. We evaluated INO against 588 industry peers in the Biotechnology industry. The financial health of INO is average, but there are quite some concerns on its profitability. INO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year INO has reported negative net income.
INO had a negative operating cash flow in the past year.
INO had negative earnings in each of the past 5 years.
INO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
INO's Return On Assets of -79.04% is on the low side compared to the rest of the industry. INO is outperformed by 71.62% of its industry peers.
INO has a Return On Equity (-115.14%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.04% | ||
| ROE | -115.14% | ||
| ROIC | N/A |
ROA(3y)-73.52%
ROA(5y)-66.86%
ROE(3y)-105.64%
ROE(5y)-772.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
INO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INO has less shares outstanding
INO has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, INO has a worse debt to assets ratio.
2.2 Solvency
INO has an Altman-Z score of -12.38. This is a bad value and indicates that INO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -12.38, INO is not doing good in the industry: 80.68% of the companies in the same industry are doing better.
There is no outstanding debt for INO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.38 |
ROIC/WACCN/A
WACC8.96%
2.3 Liquidity
A Current Ratio of 3.60 indicates that INO has no problem at all paying its short term obligations.
With a Current ratio value of 3.60, INO perfoms like the industry average, outperforming 41.03% of the companies in the same industry.
INO has a Quick Ratio of 3.60. This indicates that INO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of INO (3.60) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 |
3. Growth
3.1 Past
The earnings per share for INO have decreased strongly by -76.50% in the last year.
INO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -91.88%.
INO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -51.33% yearly.
EPS 1Y (TTM)-76.5%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q55.56%
Revenue 1Y (TTM)-91.88%
Revenue growth 3Y-51.76%
Revenue growth 5Y-51.33%
Revenue growth Q2Q-14.46%
3.2 Future
INO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.94% yearly.
Based on estimates for the next years, INO will show a quite strong growth in Revenue. The Revenue will grow by 19.62% on average per year.
EPS Next Y35.62%
EPS Next 2Y20.2%
EPS Next 3Y26.42%
EPS Next 5Y15.94%
Revenue Next Year-43.07%
Revenue Next 2Y157.26%
Revenue Next 3Y429.22%
Revenue Next 5Y19.62%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
INO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as INO's earnings are expected to grow with 26.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.2%
EPS Next 3Y26.42%
5. Dividend
5.1 Amount
No dividends for INO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INOVIO PHARMACEUTICALS INC
NASDAQ:INO (4/19/2024, 9:20:03 AM)
9.83
-0.37 (-3.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap229.73M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.04% | ||
| ROE | -115.14% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-76.5%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y35.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-91.88%
Revenue growth 3Y-51.76%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y